Diffuse large B-cell lymphoma (DLBCL) is curable in advanced stages, but up to one-third of patients will ultimately fail to respond to initial therapy. As we have now entered the molecular era of defining DLBCL, the goal is to pinpoint driver mutations and pathway addictions within distinct molecular subsets of DLBCL. This Review describes the current molecular understanding of DLBCL and discusses promising targeted approaches for each subtype.
- Mark Roschewski
- Louis M. Staudt
- Wyndham H. Wilson
